Literature DB >> 23651576

Mechanisms of cisplatin ototoxicity: theoretical review.

M S Gonçalves1, A F Silveira, A R Teixeira, M A Hyppolito.   

Abstract

INTRODUCTION: Cisplatin is an effective chemotherapeutic agent commonly used in the treatment of malignant tumours, but ototoxicity is a significant side effect.
OBJECTIVES: To discuss the mechanisms of cisplatin ototoxicity and subsequent cell death, and to present the results of experimental studies.
MATERIAL AND METHODS: We conducted a systematic search for data published in national and international journals and books, using the Medline, SciELO, Bireme, LILACS and PubMed databases.
RESULTS: The nicotinamide adenine dinucleotide phosphate oxidase 3 isoform (also termed NOX3) seems to be the main source of reactive oxygen species in the cochlea. These reactive oxygen species react with other molecules and trigger processes such as lipid peroxidation of the plasma membrane and increases in expression of the transient vanilloid receptor potential 1 ion channel.
CONCLUSION: Cisplatin ototoxicity proceeds via the formation of reactive oxygen species in cochlear tissue, with apoptotic cell death as a consequence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651576     DOI: 10.1017/S0022215113000947

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  15 in total

1.  Potential survival markers in cancer patients undergoing chemotherapy.

Authors:  Krzysztof Roszkowski; Jan Filipiak; Magdalena Wisniewska; Anna Mucha-Malecka; Pawel Basta
Journal:  Clin Exp Med       Date:  2014-09-28       Impact factor: 3.984

Review 2.  A Review of Cisplatin-Associated Ototoxicity.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Vikash Sewram
Journal:  Semin Hear       Date:  2019-04-26

3.  Cochlear protection against cisplatin by viral transfection of X-linked inhibitor of apoptosis protein across round window membrane.

Authors:  H Jie; S Tao; L Liu; L Xia; A Charko; Z Yu; M Bance; S Yin; G S Robertson; J Wang
Journal:  Gene Ther       Date:  2015-03-26       Impact factor: 5.250

4.  Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.

Authors:  Joshua M Bauml; Ravi Vinnakota; Yeun-Hee Anna Park; Susan E Bates; Tito Fojo; Charu Aggarwal; Jessica Di Stefano; Christina Knepley; Sewanti Limaye; Ronac Mamtani; Juan Wisnivesky; Nevena Damjanov; Corey J Langer; Roger B Cohen; Keith Sigel
Journal:  Cancer       Date:  2018-10-20       Impact factor: 6.860

5.  A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration.

Authors:  Changling Sun; Xueling Wang; Zhaozhu Zheng; Dongye Chen; Xiaoqin Wang; Fuxin Shi; Dehong Yu; Hao Wu
Journal:  Int J Nanomedicine       Date:  2015-05-14

Review 6.  Prevention and restoration of hearing loss associated with the use of cisplatin.

Authors:  Felician Chirtes; Silviu Albu
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

7.  Protective Effect of Tempol against Cisplatin-Induced Ototoxicity.

Authors:  Cha Kyung Youn; Jun Kim; Eu-Ri Jo; Jeonghyun Oh; Nam Yong Do; Sung Il Cho
Journal:  Int J Mol Sci       Date:  2016-11-18       Impact factor: 5.923

Review 8.  Cisplatin-Associated Ototoxicity: A Review for the Health Professional.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Vikash Sewram
Journal:  J Toxicol       Date:  2016-12-27

Review 9.  Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.

Authors:  Inés Mármol; Cristina Sánchez-de-Diego; Alberto Pradilla Dieste; Elena Cerrada; María Jesús Rodriguez Yoldi
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

Review 10.  Advances in drug delivery system for platinum agents based combination therapy.

Authors:  Xiang Kang; Hai-Hua Xiao; Hai-Qin Song; Xia-Bin Jing; Le-San Yan; Ruo-Gu Qi
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.